# US 2019/0167850 A1 · Hydrogel patch

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167850 A1
- Document ID: US20190167850A1
- Status: Published application
- Kind: A1
- Application number: 16/305,039
- Filed: 2018-03-14
- Published: 2019-06-06
- Earliest claimed: 2017-03-14
- Assignees: Unist (Ulsan National Institute of Science and Technology)
- Applicants: Unist(Ulsan National Institute of Science and Technology)
- Inventors: Jeong Beom Kim; Dong Gyu Nam
- Web page: https://patentgrep.com/patent/US20190167850A1

## CPC

- A61L 27/52: Hydrogels or hydrocolloids
- A61K 31/728: Hyaluronic acid
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/363: {Fibrinogen}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61L 27/20: Polysaccharides
- A61L 27/225: {Fibrin; Fibrinogen}
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61P 25/00: Drugs for disorders of the nervous system
- A61L 2300/236: Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/414: Growth factors
- A61L 2430/32: for nerve reconstruction
- A61L 2430/38: for reconstruction of the spine, vertebrae or intervertebral discs
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a hydrogel patch, a method of preparing the same, and a composition for the treatment of spinal cord injury including the hydrogel patch. The hydrogel patch enables a spinal cord injury patient to be treated in a manner which is non-invasive to the spinal cord.

## Claims

### Claim 1

A hydrogel patch comprising:
at least one selected from fibrin and fibrinogen;
laminin; and
hyaluronic acid or a salt thereof.

### Claim 2 (depends on 1)

The hydrogel patch of claim 1, further comprising a cell growth factor.

### Claim 3 (depends on 2)

The hydrogel patch of claim 2, wherein the cell growth factor comprises a neuronal cell growth factor, a vascular endothelial cell growth factor, a fibroblast growth factor, a bone morphogenetic protein, an epidermal growth factor, a hepatocyte growth factor, a transforming growth factor, or a combination thereof.

### Claim 4 (depends on 3)

The hydrogel patch of claim 3, wherein the neuronal growth factor comprises at least one selected from brain-derived neurotrophic factor (BDNF), a glial cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (bFGF), cyclic adenosine monophosphate (cAMP), a neurotrophin (NT), neurotropin-3 (NT3), neurotropin-4 (NT4), triiodo-L-thyronine (T3), sonic hedgehog (SHH), and platelet-derived growth factor (PDGF).

### Claim 5 (depends on 3)

The hydrogel patch of claim 3, wherein the vascular endothelial cell growth factor is vascular endothelial growth factor (VEGF).

### Claim 6 (depends on 1)

The hydrogel patch of claim 1, wherein the hydrogel patch does not include cells.

### Claim 7 (depends on 1)

The hydrogel patch of claim 1, wherein the hydrogel patch has a porous surface.

### Claim 8 (depends on 1)

The hydrogel patch of claim 1, wherein the hydrogel patch undergoes a reversible phase transition into a solid state, a semi-solid state, or a liquid state, in accordance with temperature.

### Claim 9 (depends on 1)

The hydrogel patch of claim 1, wherein a shape of the hydrogel patch conforms to a shape of an injured tissue site when the hydrogel patch is applied onto the injured tissue site.

### Claim 10 (depends on 1)

The hydrogel patch of claim 1, wherein the hydrogel patch is used for regenerating or covering an injured tissue.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The hydrogel patch of claim 1, wherein, in the hydrogel patch, a concentration of fibrin or fibrinogen is in a range of 0.5 mg/ml to 20 mg/ml, a concentration of laminin is in a range of 1 μg/ml to 100 μg/ml, or a concentration of hyaluronic acid or a salt thereof is in a range of 10 μg/ml to 5 mg/ml.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The hydrogel patch of claim 1, further comprising thrombin.

### Claim 16

A method of treating a spinal cord injury (SCI), the method including administering a hydrogel patch comprising at least one selected from fibrin and fibrinogen; laminin; and hyaluronic acid or a salt thereof to a subject in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, further comprising a cell growth factor.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 16)

The method of claim 16, wherein when the pharmaceutical composition is solid or semi-solid, the pharmaceutical composition has a porous surface.

### Claim 21 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition has the form of a powder.

### Claim 22

(canceled)

### Claim 23 (depends on 16)

The method of claim 16, wherein, in the hydrogel patch, a concentration of fibrin or fibrinogen is in a range of 0.5 mg/ml to 20 mg/ml, a concentration of laminin is in a range of 1 μg/ml to 100 μg/ml, or a concentration of hyaluronic acid is in a range of 10 μg/ml to 5 mg/ml.

### Claim 24 (depends on 16)

The method of claim 16, further comprising thrombin.

### Claim 25 (depends on 16)

The method of claim 16, wherein the spinal cord injury is a chronic spinal cord injury.

### Claim 26

A method of preparing a hydrogel patch, the method comprising adding thrombin to a sol-phase composition comprising fibrinogen, laminin, and hyaluronic acid or a pharmaceutically acceptable salt thereof, wherein the hydrogel patch is low-temperature preserved or cryopreserved in a solution at a temperature of 4° C. to −210° C.

### Claim 27

(canceled)

### Claim 28

(canceled)
